JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB257357

Human ARID2 knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

ARID2 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon2.

View Alternative Names

ARID domain-containing protein 2, ARID2_HUMAN, AT rich interactive domain 2 (ARID, RFX like), AT-rich interactive domain-containing protein 2, BAF200, BRG1-associated factor 200, DKFZp686G052, DKFZp779P0222, FLJ30619, KIAA1557, Zinc finger protein with activation potential, Zipzap/p200, p200, zip zap

2 Images
Western blot - Human ARID2 knockout HeLa cell lysate (AB257357)
  • WB

Lab

Western blot - Human ARID2 knockout HeLa cell lysate (AB257357)

Lane 1 : Wild-type HeLa cell lysate, 20 ug

Lane 2 : ARID2 knockout HeLa cell lysate, 20 ug

Lane 3 : HEK-293 cell lysate, 10 ug

Lane 4 : U-87 MG cell lysate, 10 ug

False colour image of Western blot : Anti-ARID2 antibody staining at 1/2000 dilution, shown in green; Mouse anti-Alpha Tubulin [DM1A] (ab7291) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab245529 was shown to bind specifically to ARID2. A band was observed at 220 kDa in wild-type HeLa cell lysates with no signal observed at this size in ARID2 knockout cell line ab265137 (knockout cell lysate ab257357). To generate this image, wild-type and ARID2 knockout HeLa cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 5% milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4°C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) at 1/20000 dilution.

false

Sanger Sequencing - Human ARID2 knockout HeLa cell lysate (AB257357)
  • Sanger seq

Unknown

Sanger Sequencing - Human ARID2 knockout HeLa cell lysate (AB257357)

Homozygous : 1 bp deletion in exon2

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon2.

Disease

Adenocarcinoma

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab257357-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human ARID2 knockout HeLa cell lysate", "number":"AB257357-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB257357-CMP02", "productcode":"" } ] } } }

Properties and storage information

Gene name
ARID2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

ARID2 also known as AT-rich interactive domain-containing protein 2 is a component of the SWI/SNF chromatin remodeling complex. It has a molecular mass of approximately 183 kDa. ARID2 is expressed in various tissues with high levels found in the liver kidney and testis. In the cell nucleus it functions as a DNA-binding protein playing a role in modulating chromatin structure through its interaction with other chromatin-associated proteins.
Biological function summary

ARID2 contributes to regulating gene expression by remodeling chromatin allowing transcription factors access to DNA. It acts as a part of the PBAF subtype of the SWI/SNF complex which includes proteins like BRG1 and BAF200. This complex influences transcriptional activation and repression aiding the regulation of genes important for cellular differentiation and development. Loss or mutation of ARID2 affects normal biological processes indicating its role in ensuring proper cellular function.

Pathways

ARID2 plays a role in the RAS signaling and the Hedgehog signaling pathways. It interacts with proteins such as BAF155 and BAF170 which are essential for recruiting and assembling the PBAF complex on chromatin. These pathways are critical for cellular proliferation and differentiation ensuring that cells respond accurately to signals which is vital for maintaining tissue homeostasis and proper organismal development.

ARID2 mutations are linked to hepatocellular carcinoma and malignant melanoma. These mutations are associated with abnormalities in chromatin remodeling that lead to transcriptional dysregulation. The target is also connected to proteins like BRD9 and BRD7 within the context of cancer which are involved in tumor suppression. Alterations in ARID2 might contribute to the progression and aggressiveness of these cancers by disrupting normal chromatin dynamics and gene expression patterns.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com